PharVision Advisers’s NB Bancorp NBBK Stock Holding History

PharVision Advisers’s Portfolio NBBK Stock Details NBBK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,721	Closed	-$189K	–	898
2025 Q3	$189K	Buy	+10,721	New	+$197K	0.11%	529

Other funds holding NBBK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

PharVision Advisers's NBBK Position: Q4 2025 in Review

PharVision Advisers sold out of NB Bancorp (NBBK) in Q4 2025, closing a stake of 10,721 shares — an estimated $189K sold.

PharVision Advisers first reported a position in NBBK in Q3 2025 and held it in 1 quarter. The position peaked at $189K in Q3 2025. 162 funds tracked by Wall St. Rank hold NBBK as of Q4 2025.

PharVision Advisers reported no remaining NB Bancorp position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 10,721 NB Bancorp shares in Q4 2025, an estimated $189K.
PharVision Advisers first reported a position in NB Bancorp in Q3 2025 and held it in 1 quarter.
PharVision Advisers's NB Bancorp position peaked at $189K in Q3 2025.
162 funds tracked by Wall St. Rank held NB Bancorp as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.